Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen

Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday. Bank of America dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $3.67 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The stock has a 50 day simple moving average of $4.18 and a 200 day simple moving average of $4.70. Recursion Pharmaceuticals has a 52-week low of $2.98 and a 52-week high of $7.89. The firm has a market capitalization of $1.91 billion, a PE ratio of -2.48 and a beta of 0.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 66.70%. The business’s quarterly revenue was up 671.7% on a year-over-year basis. During the same period last year, the company posted ($0.53) EPS. Sell-side analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 220,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total value of $924,000.00. Following the completion of the sale, the director owned 6,429,863 shares of the company’s stock, valued at approximately $27,005,424.60. This represents a 3.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Ben R. Taylor sold 13,426 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total transaction of $41,352.08. Following the completion of the transaction, the chief financial officer directly owned 1,195,349 shares of the company’s stock, valued at $3,681,674.92. This represents a 1.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 819,212 shares of company stock worth $3,523,950. Corporate insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares during the period. Royal Bank of Canada grew its position in shares of Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Recursion Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after purchasing an additional 12,372 shares during the period. Finally, Focus Partners Wealth acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $77,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Key Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Recursion reported narrower-than-expected Q4 loss (EPS -$0.21 vs. -$0.28 est.) and materially beat revenue estimates, driven partly by partner milestones. The results and upbeat metrics were the primary catalyst lifting the stock after the print. RXRX Q4 Loss Narrower Than Expected
• Positive Sentiment: Revenue jump / partner milestone extends runway — FY2025 revenue rose materially (reported ~$74.7M), with Roche-related milestone revenue cited as extending Recursion’s cash runway into 2028, reducing near-term financing risk. Recursion Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress — Management highlighted advancement of programs (e.g., REC-4881 entering clinical stages), signalling the company is moving from discovery to clinical validation — a tangible de‑risking step for an AI-driven biotech. Recursion Hits Clinical Milestones
• Positive Sentiment: Analyst support — Needham reaffirmed a “buy” and set an $8 price target, giving investors a visible upside case and supporting momentum after the print. Needham Rating
• Neutral Sentiment: Earnings call emphasized strategy and partnerships — Management framed 2025 as a transition year (scale data + ML + clinical starts); useful for long-term thesis but not an immediate earnings driver. Earnings Call Summary
• Neutral Sentiment: Disclosure/analysis availability — Full call transcript and presentation were posted (useful for modelers and event traders). Earnings Presentation
• Negative Sentiment: Still unprofitable and wide negative margins — Despite the beat, Recursion remains loss-making (negative net margin/ROE) and analysts forecast negative FY EPS, leaving valuation and path to sustained profitability as open questions. AAII Analysis
• Negative Sentiment: Technical / liquidity headwinds — The stock traded below key moving averages with volume below its recent average, and remains volatile; those factors can pressure price even after positive news. Market Reaction

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.